| Author (year) |
1 or more ARTI |
|
3 or more ARTI |
|
| |
OM-85 |
Placebo |
OM-85 |
Placebo |
| Schaad et al. (2002)[24] |
103 (85.8%) |
87 (87%) |
39 (32.5%) |
44 (44%) |
| Gutierrez-Tarangoand Berber (2001)[19] |
23 (85.2%) |
28 (100%) |
14 (51.9%) |
23 (82.1%) |
| Jara-Perezand Berber(2000)[17] |
86 (86%) |
100 (100%) |
14 (14%) |
70 (70%) |
| Del Rioet al. (2003)[25] |
2 (10%) |
20 (100%) |
14 (70%) |
19 (95%) |
| Paupe(1990)[21] |
37 (60.7%) |
46 (83.6%) |
19 (31.1%) |
34 (61.8%) |
| Zagarand Löfler-Badzek(1988)[26] |
8 (27.6%) |
9 (40.9%) |
1 (3.4%) |
5 (22.7%) |
| Schaadet al. (1986)[27] |
39 (86.7%) |
48 (98%) |
28 (62.2%) |
28 (57.1%) |
| Gomez-Barretoet al. (1998)[18] |
13 (50%) |
21 (70%) |
8 (30.8%) |
12 (40%) |
| Pooled
(significance: P<0.001) |
311 (72.7%) |
359 (88.9%) |
137 (32%) |
235 (58.2%) |
| Number needed to treat |
6.2 |
|
3.8 |
|
| Odds ratios OM-85: placebo |
0.33 (95% CI 0.23, 0.49) |
|
0.33 (95% CI 0.25, 0.45) |
|
| "Robust analysis" after deleting Jara-Perez[17] (2000) as positive 'outlier' &Schaad[27](1986) as negative 'outlier': |
| Pooled (significance: P<0.001) |
186 (65.7%) |
211 (82.7%) |
95 (33.6%) |
137 (53.7%) |
| *: Test for heterogeneity: P=0.001 for 1 or more ARTI, P<0.00001 for 3 or more ARTI; †: Test for heterogeneity: P>0.1. |
